XIENCE V provides superior* clinical outcomes.

XIENCE V represents the next generation of drug eluting stents. Combining Abbott’s strong legacy of leadership and innovation with excellent service and support, XIENCE V delivers a solution that you can deploy with confidence.

The best possible customer service

Abbott is dedicated to offering hospitals the support they need to find products and answer questions. Below are resources designed just for you.

Country Customer Service Contact Phone Number
Sweden 46 (0) 8 546 56 951
Finland 46 (0) 8 546 56 951
Norway 46 (0) 8 546 56 952
Denmark 46 (0) 8 546 56 952
Austria 43 1 89122458
UK 44 1628 774 968
Italy 39 02 51 625 130
Spain 34 9 13370687
Germany 49 800 1 80 81 93
France 01 47 14 40 05
South Asia (India, Pakistan, Bangladesh, Sri Lanka) 91 11 4053 0113
Australia +61 1800 550 939
Hong Kong +852-2593-2288
India +91-11-5162-8547
   

International XIENCE V product numbers and bar codes

Easily locate XIENCE V product numbers and bar codes to order products and confirm inventory.

Download product numbers and bar code list

Patient Information Guide

Ensure that patients have all the information they need about coronary artery disease (CAD) and the XIENCE V stent system. The XIENCE V Patient Information Guide illustrates the stent procedure and outlines the risks and benefits of treating with XIENCE V.

Download English version Download Spanish version

* In SPIRIT II, XIENCE V demonstrated superiority versus TAXUS stents with a statistically significant 69% reduction in the primary endpoint of in-stent late loss at 6 months (0.11mm vs 0.36mm; PNI and PSUP<0.0001). Both TAXUS Express2 (73% of lesions) and TAXUS Liberte (27% of lesions) were used as controls in SPIRIT II. Source: P. Serruys et al. EuroIntervention 2006; 2:286-294 & data on file at Abbott Vascular. In SPIRIT III, XIENCE V demonstrated superiority versus TAXUS Express2 with a statistically significant 50% reduction in the primary endpoint of in-segment late loss at 8 months (0.14mm vs 0.28mm; PNI <0.0001, PSUP=0.004). Source: G. Stone et al. JAMA 2008; 299(16):1903-1913.

TAXUS, TAXUS Liberte, TAXUS Express2 are registered trademarks of Boston Scientific and its affiliates.